AR029329A1 - Compuesto y uso del mismo en la fabricacion de un medicamento util para inhibir metaloproteinasas de matriz - Google Patents

Compuesto y uso del mismo en la fabricacion de un medicamento util para inhibir metaloproteinasas de matriz

Info

Publication number
AR029329A1
AR029329A1 ARP000100349A ARP000100349A AR029329A1 AR 029329 A1 AR029329 A1 AR 029329A1 AR P000100349 A ARP000100349 A AR P000100349A AR P000100349 A ARP000100349 A AR P000100349A AR 029329 A1 AR029329 A1 AR 029329A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
alkoxy
hydrogen
independently selected
Prior art date
Application number
ARP000100349A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Dellaria
Yan Guo
Lian Hong Xu
Alan Florjancic
Jian Chung Gong
C Wada
Stacy-Jamie Giesler
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR029329A1 publication Critical patent/AR029329A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP000100349A 1999-01-27 2000-01-26 Compuesto y uso del mismo en la fabricacion de un medicamento util para inhibir metaloproteinasas de matriz AR029329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
AR029329A1 true AR029329A1 (es) 2003-06-25

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100349A AR029329A1 (es) 1999-01-27 2000-01-26 Compuesto y uso del mismo en la fabricacion de un medicamento util para inhibir metaloproteinasas de matriz

Country Status (28)

Country Link
US (1) US20020007060A1 (enExample)
EP (1) EP1147101B1 (enExample)
JP (1) JP4718686B2 (enExample)
KR (1) KR100748010B1 (enExample)
CN (1) CN1222519C (enExample)
AR (1) AR029329A1 (enExample)
AT (1) ATE228122T1 (enExample)
AU (1) AU764383B2 (enExample)
BG (1) BG105782A (enExample)
BR (1) BR0007278A (enExample)
CA (1) CA2358951C (enExample)
CO (1) CO5150194A1 (enExample)
CZ (1) CZ20012591A3 (enExample)
DE (1) DE60000819T2 (enExample)
DK (1) DK1147101T3 (enExample)
ES (1) ES2187443T3 (enExample)
HK (1) HK1043115A1 (enExample)
HU (1) HUP0105477A2 (enExample)
IL (1) IL143713A0 (enExample)
NO (1) NO20013669L (enExample)
NZ (1) NZ512372A (enExample)
PL (1) PL349771A1 (enExample)
PT (1) PT1147101E (enExample)
SK (1) SK10582001A3 (enExample)
TR (1) TR200102159T2 (enExample)
TW (1) TWI225486B (enExample)
WO (1) WO2000044739A1 (enExample)
ZA (1) ZA200104979B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780386B1 (en) * 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2358951A1 (en) 2000-08-03
AU2739100A (en) 2000-08-18
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
IL143713A0 (en) 2002-04-21
HUP0105477A2 (hu) 2002-05-29
TR200102159T2 (tr) 2001-12-21
BG105782A (en) 2002-04-30
US20020007060A1 (en) 2002-01-17
SK10582001A3 (sk) 2001-12-03
NO20013669D0 (no) 2001-07-26
EP1147101A1 (en) 2001-10-24
WO2000044739A1 (en) 2000-08-03
PL349771A1 (en) 2002-09-09
NZ512372A (en) 2003-01-31
TWI225486B (en) 2004-12-21
ATE228122T1 (de) 2002-12-15
CN1339032A (zh) 2002-03-06
BR0007278A (pt) 2001-11-27
ZA200104979B (en) 2002-09-18
NO20013669L (no) 2001-09-27
EP1147101B1 (en) 2002-11-20
DE60000819D1 (de) 2003-01-02
CZ20012591A3 (cs) 2001-12-12
DE60000819T2 (de) 2003-09-04
CO5150194A1 (es) 2002-04-29
PT1147101E (pt) 2003-04-30
DK1147101T3 (da) 2003-03-10
AU764383B2 (en) 2003-08-14
CA2358951C (en) 2009-10-20
KR20010101709A (ko) 2001-11-14
CN1222519C (zh) 2005-10-12
KR100748010B1 (ko) 2007-08-09
ES2187443T3 (es) 2003-06-16
JP4718686B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
RU2424240C2 (ru) Антибактериальные производные пиперидина
AR062319A1 (es) Derivados de 2-(heterociclilbencil)-piridazinona, un procedimiento para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades afectadas por la inhibicion de la met-quinasa y un kit para su utilizacion.
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR058362A1 (es) Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
KR960014121A (ko) 아로일-피페리딘 유도체
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
AR055878A1 (es) Derivados de ciclopropanocarboxamida
CA2505033A1 (en) Non-nucleoside reverse transcriptase inhibitors
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0315966D0 (en) Compounds
MX9606541A (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
DK1258484T3 (da) Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
KR900006342A (ko) 1,4-디아제핀 유도체 및 그의 약학적 이용
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
AR061438A1 (es) Derivados de entacapone
SE9703377D0 (sv) New compounds
KR930702288A (ko) 타이졸리딘디온 유도체
AR029329A1 (es) Compuesto y uso del mismo en la fabricacion de un medicamento util para inhibir metaloproteinasas de matriz
MX9202438A (es) Esteroides 3-carboxi insaturados substituidos en la posicion 17 beta, procedimiento para su preparacion y composicion farmaceutica que los contiene.
JP2007514639A5 (enExample)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal